Second Generation Antibodies Neutralize Emerging SARS-CoV-2 Variants of Concern
Kovacech, B.; Fialova, L.; Filipcik, P.; Zilkova, M.; Skrabana, R.; Paulenka-Ivanovova, N.; Kovac, A.; Palova, D.; Paulikova Rolkova, G.; Tomkova, K.; Turic Csokova, N.; Markova, K.; Skrabanova, M.; Sinska, K.; Basheer, N.; Majerova, P.; Hanes, J.; Parrak, V.; Prcina, M.; Cehlar, O.; Cente, M.; Piestansky, J.; Fresser, M.; Novak, M.; Slavikova, M.; Borsova, K.; Cabanova, V.; Brejova, B.; Vinar, T.; Nosek, J.; Klempa, B.; Zilka, N.; Kontsekova, E.
Show abstract
Recently emerged SARS-CoV-2 variants show resistance to some antibodies that were authorized for emergency use. We employed hybridoma technology combined with authentic virus assays to develop second-generation antibodies, which were specifically selected for their ability to neutralize new variants of SARS-CoV-2. AX290 and AX677, two monoclonal antibodies with non-overlapping epitopes, exhibit subnanomolar or nanomolar affinities to the receptor binding domain of the viral Spike protein carrying amino acid substitutions N501Y, N439K, E484K, K417N, and a combination N501Y/E484K/K417N found in the circulating virus variants. The antibodies showed excellent neutralization of an authentic SARS-CoV-2 virus representing strains circulating in Europe in spring 2020 and also the variants of concern B.1.1.7 and B.1.351. Finally, the combination of the two antibodies prevented the appearance of escape mutations of the authentic SARS-CoV-2 virus. The neutralizing properties were fully reproduced in chimeric mouse-human versions, which may represent a promising tool for COVID-19 therapy.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses 95%
- An enzyme-based immunodetection assay to quantify SARS-CoV-2 infection 94%
- Defining functional neuraminidase inhibitor drug resistance motifs in avian influenza viruses and the consequential impact on virus fitness in chicken cells. 94%
Similar papers in this journal
- A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern 96%
- Differential recognition of computationally optimized H3 hemagglutinin influenza vaccine candidates by human antibodies 96%
- Mutations in S2 subunit of SARS-CoV-2 Omicron spike strongly influence its conformation, fusogenicity and neutralization sensitivity 95%
Similar papers in this journal
- Biosynthetic proteins targeting the SARS-CoV-2 spike as anti-virals 96%
- A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 delta variant 96%
- Nasal delivery of single-domain antibodies improve symptoms of SARS-CoV-2 infection in an animal model 96%
Similar papers in this journal
Similar papers in this journal
- An ACE2 decamer viral trap as a durable intervention solution for current and future SARS-CoV 95%
- One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization 94%
- Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.